0B68 Sharma, Manish - Thomas Jefferson University - Thomas Jefferson University

Manish Sharma, MD

Contact Dr. Sharma

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma
  2. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma
  3. Reverse warburg effect in a patient with aggressive B-cell lymphoma: Is lactic acidosis a paraneoplastic syndrome?
  4. Severe irinotecan-induced toxicity in a patient with UGT1A1*28 and UGT1A1*6 polymorphisms
  5. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients
  6. Estimation of renal cell carcinoma treatment effects from disease progression modeling
  7. Models of excellence: Improving oncology drug development
  8. Why RECIST works and why it should stay - Counterpoint
  9. RECIST: No longer the sharpest tool in the oncology clinical trials toolbox - Point/Counterpoint
  10. Why RECIST works and why it should stay--reply to counterpoint.
  11. Dasatinib in previously treated metastatic colorectal cancer: A phase II trial of the University of Chicago Phase II Consortium
  12. Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant
  13. Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant
  14. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid
  15. Resampling phase III data to assess phase II Trial designs and endpoints
  16. Role of randomized phase III trials in an era of effective targeted therapies
  17. Spontaneous graft versus host disease occurring in a patient with multiple myeloma after autologous stem cell transplant
  18. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib
  19. Reversible Ureteral Obstruction due to Polyomavirus Infection after Percutaneous Nephrostomy Catheter Placement
  20. Randomized phase II Trials: A long-term investment with promising returns